Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Status:
Not yet recruiting
Trial end date:
2028-12-05
Target enrollment:
Participant gender:
Summary
This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in
patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as durvalumab, may help the body's immune system attack the cancer and may
interfere with the ability of tumor cells to grow and spread. Giving regorafenib and
durvalumab may work better in treating patients with high-risk liver cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Academic and Community Cancer Research United
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins